Abbott Laboratories experienced a price decline of approximately 22% from its 52-week high of $141.23 to a recent trough near $110 in January 2026. This pullback followed a mixed Q4 report but reflects broader market volatility rather than fundamental deterioration. With the stock trading near its 52-week low of $105.78, valuation metrics have improved: the forward P/E is now below 24x, compared with a five-year average closer to 26x, while free cash flow yield stands near 4.5%. Long-term investors can view this retracement as an opportunity to accumulate shares at a discount to historical norms.

In Q4 2025, Abbott reported revenues of $11.46 billion, marking 4.4% year-over-year growth but missing consensus estimates by roughly $340 million. Nutrition sales declined 8–9% due to ongoing volume pressures in key emerging-market franchises, while Diagnostics performance moderated as COVID-related testing demand normalized. These headwinds were offset by MedTech growth of nearly 12%—driven by continued uptake of cardiovascular and neuromodulation devices—and Established Pharmaceuticals rising 9%. Adjusted EPS came in at $1.50, aligning with Street forecasts, and full-year EPS grew 10% to $5.15. Management has guided 2026 adjusted EPS of $5.55–$5.80 and sales growth of 6.5%–7.5%, backed by cost initiatives and a robust R&D pipeline.

Twenty-two analysts currently cover Abbott, with 17 recommending buy, 2 strong buy and 3 hold. Following the Q4 release, several firms trimmed their 12-month targets—Citigroup reduced its objective from $155 to $140, Sanford Bernstein from $154 to $125 and RBC from $147 to $135—while sustaining outperform or buy ratings. The consensus target now sits around $140.79. The average price target implies upside of roughly 25% from current levels. Analysts cite margin expansion, an upcoming diagnostic platform refresh and cost-synergy capture from recent acquisitions as key catalysts supporting this view.

Indian authorities have launched an inquiry into the supply chain of Abbott’s Phensedyl codeine-based cough syrup after discovering that 22 million bottles—valued at approximately $55 million—were distributed in Uttar Pradesh between April 2024 and March 2025, far exceeding estimated therapeutic demand. Although Abbott halted domestic production of Phensedyl in December 2024 and has not been formally accused of wrongdoing, regulators inspected the Himachal Pradesh manufacturing facility on January 14 and obtained distribution records. Any adverse findings could lead to reputational damage and additional compliance costs in a high-growth emerging market.